Background: The approval of the tyrosine kinase inhibitor sorafenib in 2007 marked
| INTRODUCTION
Hepatocellular carcinoma (HCC) is the most common primary liver cancer, 1 usually develops in patients with liver cirrhosis, 2, 3 and represents the second most common cause of cancer-related death. 4 Potential curative therapies include resection, liver transplantation, and local ablative therapies, but these are reserved for early stages, characterised by small tumours limited to the liver. Transarterial chemoembolzation (TACE) and systemic therapies are the only available treatment options in the palliative setting, 5 while transarterial radioembilisation is struggling (and currently unable) to find a place in the evidence-based treatment landscape. [6] [7] [8] Patients with either symptomatic disease (performance status 1-2), macrovascular tumour invasion, or extrahepatic metastases (advanced stage HCC)
are classical candidates for systemic treatment according to current guidelines. 5 Patients with multifocal HCC and compensated liver disease (intermediate stage HCC) should be treated with TACE. 5 However, these patients may become candidates for systemic therapies under certain circumstances ( Figure 1 ): if they fail to respond to TACE (failure of 2 rounds of TACE), develop untreatable progression (major intrahepatic progression, macrovascular invasion, metastasis, symptomatic progression), show deterioration of liver function (ascites, decompensation), 9, 10 or show unfavourable disease characteristics at baseline (Hepatoma arterial-embolisation prognostic score C or D; Barcelona-Clinic Liver Cancer B subclass 3 or 4; STATE score <18). [11] [12] [13] Liver function in particular should be monitored cautiously as even discrete subclinical worsening of liver function is associated with poorer outcome after repeated TACE. 14, 15 To date, only tyrosine kinase inhibitors have been approved globally and additionally an immune checkpoint inhibitor in the United
States only. 16 Conventional chemotherapy is not recommended in HCC due to lack of efficacy, 5 and only recently two phase III studies testing chemotherapy in advanced HCC again failed. 17, 18 Whether a subset of patients with HCC may have some benefit from chemotherapy 19 needs to be confirmed in larger studies.
This review focuses on the evolution of targeted therapies since the approval of sorafenib, including failures and recent advances, and discusses the unmet need of biomarker-driven treatment strategies as well as the emerging field of immunotherapy in HCC.
| TARGETED THERAPIES

| Sorafenib
For the longest time no effective drug treatment was available for patients with HCC until the unprecedented success of the multityrosine kinase inhibitor sorafenib. The approval in 2007 was based on the positive results of the well-known SHARP study, a randomised controlled phase III trial, which showed a significant prolongation of median overall survival (OS) for sorafenib vs placebo (10.7 vs 7.9 months; hazard ratio (HR), 0.69), reflecting an extension of OS by 44%. 20 A second phase III trial conducted in the Asia-Pacific region showed similar results regarding HR, even though patients in both groups had a shorter absolute OS compared to patients in the SHARP trial (Table 1) . This was probably because of the enrolment of patients with more advanced disease in terms of extrahepatic spread, number of intrahepatic lesions, alpha-Fetoprotein (AFP), and performance status. 21 Hence, sorafenib showed a survival benefit in two independent phase III trials conducted in different geographic regions, and became the standard of care for advanced HCC. 3, 5 Side effects were mostly mild to moderate and manageable, with diarrhoea and dermatological side effects (eg hand-foot-skin reaction, rash, pruritus) being the most frequent and troublesome adverse events. 20, 21 The occurrence of dermatological events was later shown to be associated with a better outcome. 22, 23 The efficacy of sorafenib is likely a result of the fine balance between its antitumour effects and the mild and manageable toxicity profile. 24 A potential beneficial effect of sorafenib on the portal hypertensive syndrome, which may contribute to the improved survival in HCC patients, was reported in experimental models 25 and small clinical pilot studies 26, 27 but not yet confirmed in large prospective trials.
Notably, both phase III trials included only patients with well-preserved liver function, a common practice in HCC studies to avoid a potential masking of a drug-induced antitumour effect by death from underlying liver disease. 3, 28 Data from our real-life cohort 29 and that of others 30 showed that the Child-Pugh score was a strong predictor for OS (median OS for Child-Pugh A/B/C, 11.3/5.5/1.6 months
29
).
These data were confirmed by the GIDEON study, a large global prospective noninterventional phase IV observational study. 31 Con- 5 Large studies failed to show a benefit of sorafenib in the adjuvant setting or in combination with loco-regional therapies. the therapeutic armamentarium, we had to witness several compounds failing in randomised controlled phase III trials, both in the first-line (sunitinib, brivanib, linifanib, erlotinib [37] [38] [39] [40] ) and second-line (brivanib, everolimus, ramucirumab [41] [42] [43] ) setting ( Figure 2 ).
| Failed phase III trials
Potential reasons for failure have been discussed elsewhere, 24 and include high toxicity (sunitinib 38 ), modest efficacy (erlotinib, linifanib, brivanib, everolimus 37, 39, 40, 42 ), noninferiority design with a small window of opportunity (linifanib, brivanib 37, 39 ), and a clinical imbalance between the test and placebo arm (brivanib 41 ).
Notably, most drugs proceeded to phase III based on efficacy data obtained from small single-arm phase II studies, often using surrogate endpoints such as radiological response, TTP, or PFS. These surrogate endpoints are only poor predictors of OS in HCC, where even a significant response often does not translate into a survival benefit. 41, 43 Additionally, composite endpoints (eg, PFS) are vulnerable, as death from underlying cirrhosis may mask potential drug effects, and are generally discouraged as primary endpoints in HCC trials. 28 It was recently recommended that drugs should be tested in properly powered phase II studies with a control arm or at least with a large enough sample size in order to minimise a potential selection bias and random errors; the use of OS as a primary endpoint should also be considered in these trials. 24 However, with more drugs becoming available in the second-and third-line setting influencing the outcome of HCC patients, OS may not adequately reflect the effect of a tested first-line treatment, making future trial design even more difficult.
Moreover, the pattern of progression during sorafenib therapy influences postprogression survival and could therefore affect the results of second-line trials. 44 Given that the failed second-line phase III trials were designed before the publication of these important findings, none of the studies stratified patients according to the pattern of progression. Thus, it could well be that an enrichment of the worse progression pattern (new extrahepatic lesion/macrovascular invasion) may have occurred in the test arm, masking a potential drug effect. 44, 45 Finally, since HCC can be diagnosed by radiology alone in patients with liver cirrhosis, 5 a tumour biopsy, allowing tissue-based biomarker analysis to potentially rescue a drug at least in a subset of patients, was not mandatory in most phase III trials. 24 
| Recent advancements
After the approval of sorafenib, it took almost a decade until another drug could succeed in phase III, and again it was a multityrosine kinase inhibitor tested in an unselected "all-comer" cohort.
Regorafenib was evaluated in a second-line phase III trial (RESORCE) and demonstrated a significant survival benefit compared to placebo (median OS, 10.6 vs 7.8 months; HR 0.63). 46 Similar to the phase III trials of sorafenib, 20, 21 only patients with ChildPugh stage A were allowed in order to minimise a potential confounding effect of advanced liver cirrhosis on OS. Because of the similar toxicity profile of both drugs, patients intolerant to sorafenib were excluded. 46 Hence, no conclusions can be made about the efficacy of regorafenib in patients intolerant to sorafenib and in those with more advanced liver dysfunction (Child-Pugh B). 46 The most common adverse events were mostly of mild grade and included hand-foot-skin reaction, fatigue, and diarrhoea. However, including only patients who tolerated sorafenib could have reduced the occurrence of severe side effects. 46 As previously shown for sorafenib, 22 development of hand-foot-skin reaction was associated with improved survival with regorafenib in an exploratory retrospective analysis. 47 Unlike in the negative second-line study of brivanib, 41 stratification was done separately for macrovascular invasion and extrahepatic spread and therefore allowed both prognostic variables to be well balanced between the groups. Even though not a stratification factor, the pattern of progression was equally distributed between both arms, 46 which may have contributed to the positive outcome of this study. Regorafenib was finally approved for the indication "HCC" in 2017 in Europe and the United States.
Based on promising results of a phase II study, 48 the multityrosine kinase inhibitor lenvatinib was tested against sorafenib in a phase III trial with the primary endpoint being noninferiority in OS (noninferiority margin: upper limit of the two-sided 95% confidence interval for HR below 1.08). 49 Only patients with Child-Pugh stage A were included and patients with extensive tumour load (≥50% of the liver), bile duct invasion, or invasion of the main portal vein were excluded. Dosing of lenvatinib was based on body weight (8 mg <60 kg and 12 mg ≥60 kg once daily), 49 as lenvatinib exposure was influenced by body weight in the phase II study. 48 The study finally reached its primary endpoint with a HR of 0. Taken together, lenvatinib was noninferior compared to sorafenib in terms of overall survival in the first-line setting and will be added to the treatment armamentarium shortly. No data are available on the efficacy of lenvatinib in patients with main portal vein invasion or a tumour load ≥50% of the liver as these patients were excluded from the study.
Regorafenib was the first drug to show a prolongation of survival in the second-line setting and has been approved for patients who have been previously treated with sorafenib. The magnitude of benefit was similar to that of sorafenib. Patients who progress on sorafenib are the best candidates for regorafenib while those intolerant to sorafenib may also not tolerate regorafenib very well. As the CELESTIAL trial allowed inclusion of patients who discontinued sorafenib due to adverse events, cabozantinib may become the preferred second-line option in patients intolerant to sorafenib, once approved by regulatory agencies.
Notably, as none of these agents was tested in Child-Pugh B patients, only patients with well-preserved liver function may be treated until data for Child-Pugh B patients become available and support the use of these drugs in this indication. The limited efficacy of the different agents (Table 1 ) may partly be owed to the lack of a biomarker for treatment selection, as discussed in the next paragraph.
| Biomarkers for patient selection
Unlike "all-comer" trials, study inclusion based on oncogenic drivers or biomarkers for activated signalling pathways ensures that the molecular target is present in the studied population, 24 The mTOR inhibitor everolimus was tested in a phase III trial in the second-line setting against placebo. 42 This pathway is activated in around half of all HCCs and associated with a worse outcome. 55, 56 Given the high frequency of aberrant mTOR signalling in HCC, one could expect at least some improvement in OS if everolimus was active, even though the study was performed in "all-comers".
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Despite this strong theoretical rationale for the use of everolimus in HCC, final results did not even show a trend in survival (everolimus vs placebo, 7.6 vs 7.3 months).
A proof-of-principle trial evaluated the MEK inhibitor refametinib alone or in combination with sorafenib in patients with RAS-mutated HCC. 57 The study was based on promising results of a phase II study showing better response rates for the combination of refametinib plus sorafenib in HCC patients with mutated RAS compared to wild-type RAS. 58 Of 498 patients in the monotherapy and 820 patients in the combination arm included, the prevalence of RAS mutation was 6.5% and 3.3%, respectively, and 16 patients in each group finally received treatment. Given the insufficient efficacy with no confirmed response for refametinib alone and only one confirmed partial response for the combination arm this approach was not further pursued in HCC. 57 The MET inhibitor tivantinib was investigated in a second-line randomised controlled phase II study where it only improved survival in patients with high tumoral MET expression but not in cases with MET-low HCC. 59 These results prompted the conduction of a phase III trial (METIV-HCC) testing tivantinib vs placebo only in patients with high MET expression. 60 However, the high expectations for tivantinib to become the first biomarker-driven treatment approach in HCC could not be fulfilled, as recently presented results did not
show an improvement of the primary endpoint OS (median OS for tivantinib vs placebo, 8.4 vs 9.1 months). 60 Tivantinib also failed in a similar phase III (JET-HCC) study conducted in Japan only. 61 While brivanib, a multityrosine kinase inhibitor with activity against FGF receptors, failed in two phase III trials in unselected "all- Ramucirumab, a monoclonal antibody against VEGF receptor-2, was investigated in a second-line phase III randomised controlled trial (REACH). While ramucirumab failed to improve the primary endpoint OS in the whole cohort, patients with elevated serum AFP did much better on ramucirumab than on placebo (median OS, 7.8 vs
months)
. 43 Based on these data, another phase III randomised controlled trial (REACH-2) has been conducted testing ramucirumab vs placebo in sorafenib-experienced patients with AFP of 400 ng/mL or higher. As recently reported, ramucirumab moderately but significantly prolonged survival (median OS, 8.5 vs 7.3 months) with a HR of 0.71 (95% CI, 0.53-0.95), making ramucirumab the first drug that showed a survival benefit in a biomarker-selected population. 62 Hence, ramucirumab-the first biomarker-guided treatment in HCC-will likely become a preferred option in patients with AFP ≥400 ng/mL, and especially in those with poor tolerance to tyrosine kinase inhibitors.
The difficult mission of setting up successful biomarker-enriched trials in HCC is at least in parts a result of the complex tumour biology. HCC is heterogeneous 63 and the molecular profile obtained by a single biopsy does not guarantee that it is actually representative for the whole tumour load, especially in multifocal HCC. 22 Additionally, the expression of a target or the activation of a certain signalling cascade does not categorically imply tumour dependency. 64 These aspects further complicate the identification of tissue biomarkers to guide treatment decisions in HCC. Nevertheless, all efforts towards a personalised HCC therapy should be made and acquiring tissue samples for molecular profiling seems to be indispensable to achieve this goal. 65 
| IMMUNOTH ERAPY
| Rationale
Immunotherapy has become a mainstay in the treatment of certain malignancies including melanoma and lung cancer. 66 There are also several reasons why immunotherapy may be feasible and effective in HCC. 67, 68 HCC is an immunogenic tumour as spontaneous regres- 75 The latter ones will be discussed herein, as this strategy is already in advanced clinical testing in HCC and clinical data from early trials have been promising.
| Immune checkpoint blockers
Immune checkpoint receptors (eg PD-1, cytotoxic T-lymphocyte- Preliminary results of a phase I/II trial investigating durvalumab, a mAb against programmed cell death 1 ligand 1 (PD-L1), in 40 patients (92.5% received prior sorafenib) with advanced HCC were recently reported. 79 Four patients had PR (all confirmed), which occurred early and were durable; the DCR at ≥24 weeks was 32.5%.
Median PFS and OS were 2.7 months and 13.2 months, respectively.
Most common AEs were fatigue, pruritus, and elevated aminotrans- 
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Taken together, results from uncontrolled phase I/II studies testing checkpoint inhibitors in HCC are encouraging but need to be confirmed in large randomised controlled trials. Table 3 provides a list of phase III studies evaluating checkpoint inhibitors in HCC.
| Combination strategies with immune checkpoint inhibitors
Several strategies combining immune checkpoint blockers with other treatment modalities are under investigation for different stages of HCC, and the combination of different checkpoint blockers in advanced stage disease is one of them.
The combined use of nivolumab and ipilimumab (anti-CTLA -4) improves not only the efficacy in melanoma patients compared to ipilimumab alone but also increases toxicity. 84 The combination of these compounds is currently under investigation in HCC (NCT01658878).
Durvalumab combined with tremelimumab is being tested in a large four-arm phase III study as first-line treatment in patients with unresectable HCC (NCT03298451) ( (Table 2) . 91 Similarly, the combination of atezolizumab (anti-PD-L1) and bevacizumab was well tolerated and showed promising preliminary efficacy results (ORR, 65%) as a first-line treatment in advanced HCC (Table 2) . be an option in patients with HCC recurrence after liver transplantation is also subject to further studies. Notably, a patient with pulmonary recurrence after living donor liver transplantation for HCC, who progressed on sorafenib showed complete radiological remission to pembrolizumab despite ongoing immunosuppression and without signs of graft rejection. 99 However, nivolumab led to fatal A renaissance of the tumour biopsy may be inevitable to achieve the unmet need of individualised therapy, 65 and acquisition of tumour tissue and serum samples for biomarker analysis should become a routine in clinical HCC trials.
Liquid biopsy could become an alternative to tissue biomarkers as it may provide an even more comprehensive profile of the cancer than that derived from small tumour specimens. 113 However, unlike in other solid tumours such as lung cancer, 114 liquid biopsy is not yet ready for clinical use in HCC, since large-scale studies using standardised techniques and uniform methodology are lacking. 115 It also remains unclear if liquid biopsy can adequately reflect the immune tumour microenvironment.
Biomarkers to predict response to checkpoint blockers are also lacking in HCC. Neither tumoral PD-L1 expression nor baseline AFP predicted response to nivolumab in HCC. 80, 81 The intratumoral infiltration of CD8+ T cells during tremelimumab treatment was associated with better outcome in a pilot study; however, only a few patients were evaluable and serial tumour biopsy is required, 93 thus, limiting its use in clinical routine. Other approaches to predict response to immunotherapy including gut microbiota 116, 117 or monocytes in the peripheral blood 118 need further prospective evaluation.
